| Identification | More | [Name]
Bleomycin sulfate | [CAS]
9041-93-4 | [Synonyms]
BLENOXANE
BLEO
BLEOMYCIN SULFATE
BLEOMYCIN SULFATE, STREPTOMYCES VERTICILLUS
BLEOMYCIN SULPHATE
BLEXANE
Blenmycins
bleomycin,sulfate(salt)
NSC-125066
bleomycin sulfate from streptomyces verticillus
BLEOMYCIN SULFATE CELL CULTURE TESTED
BLEOMYCIN SULFATE, BPC
BLEOMYCIN SULFATE FROM STREPTOMYCES VERT ICILLUS, LYOPH.
BLEOMYCIN SULFATE FROM STREPTOMYCES VERTICILLUS 0 TO 5 °C
Blocamicina
BLEMOYCIN SULFATE
3-[[2-[2-[2-[2-[4-[2-[6-Amino-2-[1-(2-amino-2-carbamoyl-ethyl)amino-2-carbamoyl-ethyl]-5-methyl-pyrimidin-4-yl]carbonylamino-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-3-(3H-imidazol-4-yl)propanoyl]amino-3-hydroxy-2-methyl-pentanoyl]amino-3-hydroxy-butanoyl]aminoethyl]-1,3-thiazol-4-yl]-1,3-thiazol-4-yl]carbonylamino]propyl-dimethyl-sulfonium hydrogen sulfate
Bleomycin Sulfate, Blenoxane
Bleomycin Sulfate (A mixture of bleomycin sulfate salts)
Blenoxane, Bleo, Blexane | [EINECS(EC#)]
232-925-2 | [Molecular Formula]
C110H168N34O46S7 | [MDL Number]
MFCD00070310 | [Molecular Weight]
2927.17 | [MOL File]
9041-93-4.mol |
| Chemical Properties | Back Directory | [Appearance]
White Powder | [Melting point ]
200-204°C (dec.) | [storage temp. ]
2-8°C
| [solubility ]
H2O: 20 mg/mL
| [form ]
powder
| [color ]
white
| [Water Solubility ]
Soluble in water or DMSO | [Usage]
A group of related glycopeptide antibiotics. Bleomycin A2 is the main component of the bleomycin employed clinically.
Antineoplastic | [Merck ]
13,1311 | [Stability:]
Stable for 1 year from the date of purchase. Solutions in distilled water may be stored at -20°C for up to 3 months. | [CAS DataBase Reference]
9041-93-4(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
T,Xi | [Risk Statements ]
R40:Limited evidence of a carcinogenic effect.
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S53:Avoid exposure-obtain special instruction before use .
S36/37:Wear suitable protective clothing and gloves .
S45:In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) .
S36:Wear suitable protective clothing .
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice . | [WGK Germany ]
3
| [RTECS ]
EC5991990
| [F ]
10 | [HS Code ]
2941906000 |
| Hazard Information | Back Directory | [Description]
Bleomycin sulfate (9041-93-4) coordinates with metals producing reactive oxygen species which causes oxidative damage to DNA1?and RNA2. Induces double-strand DNA damage.3?Commonly used to induce lung fibrosis in animal disease models.4,5?Anticancer agent in clinical use.6 | [Chemical Properties]
White Powder | [Uses]
A group of related glycopeptide antibiotics. Bleomycin A2 is the main component of the bleomycin employed clinically.
Antineoplastic | [Uses]
Bleomycin is a complex of 11 glycopeptide antitumor antibiotics originally isolated from Streptomyces verticillus in 1972. The dominant components of the complex are bleomycin A2 and B2, which typically represent >90% of the total weight. Bleomycins have found clinical application in the treatment of a range of tumors. Bleomycins act by intercalation of DNA and RNA. In the presence of oxygen and metal ions, notably copper and iron, bleomycins form a pseudo-enzyme that induces DNA cleavage. | [Uses]
Bleomycin is a complex of 11 glycopeptide antitumour antibiotics originally isolated from Streptomyces verticillus in 1972. The dominant components of the complex are bleomycin A2 and B2, which typically represent >90% of the total weight . Bleomycins have found clinical application in the treatment of a range of tumours. Bleomycins act by intercalation of DNA and RNA. In the presence of oxygen and metal ions, notably copper and iron, bleomycins form a pseudo-enzyme that induces DNA cleavage. | [Brand name]
Blenoxane (Bristol-Myers Squibb). | [General Description]
Bleomycin occurs as a white powder and is available in 15-and 30-U vials for reconstitution in water. It may be givenintravenously, intramuscularly, or subcutaneously. It is used in the treatment of squamous cell carcinoma of the headneck, cervix, penis, and vulva. It is also used in Hodgkin’sand non-Hodgkin’s lymphoma as well as testicular carcinoma.Unlabeled uses include the treatment of mycosis fungoides,osteosarcoma, and AIDS-related Kaposi sarcoma. | [Biochem/physiol Actions]
Bleomycin sulfate binds to DNA, causes ssDNA scission at specific base sequences and inhibits DNA synthesis. This inhibitory action requires bleomycin to bind oxygen and a metal ion. It can also cleave RNA, to a lesser degree but more selectively. It acts as an inducer and regulator of apoptosis and inhibits tumor angiogenesis. | [Clinical Use]
Bleomycin is used IV in the palliative treatment of squamous cell head and neck cancers, testicular and other genital carcinomas, and Hodgkin's and non-Hodgkin's lymphoma. | [Side effects]
It is excreted via the kidneys, and serum concentrations of active drug are increased in patients with renal disease. The elimination half-life can rise from 2 to 4 hours to more than 20 hours in renal failure, resulting in significant toxicity, especially pulmonary toxicity. | [Veterinary Drugs and Treatments]
Bleomycin has occasionally been used as adjunctive treatment of
lymphomas, squamous cell carcinomas, teratomas, and nonfunctional
thyroid tumors in both dogs and cats. Recent work has demonstrated
that bleomycin may be promising for intralesional treatment
for a variety of localized tumors with or without concomitant
electropermeabilization. | [target]
UT-SCC-129 cells | [References]
1) Petering?et al.?(1990),?The role of redox-active metals in the mechanism of action of bleomycin; Chem. Biol. Interact.,?73?133
2) Huttenhofer?et al. (1992),?Cleavage of tRNA by Fe(II)-bleomycin; J. Biol. Chem.,?267?24471
3) Lee?et al.?(2017)?ASF1a Promotes Non-homologous End Joining Repair by facilitating Phosphorylation of MDC1 by ATM at Double-Strand Breaks;?Mol. Cell?68?61
4)?Xie?et al.?(2016), Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis; Respir. Res.,?17?103
5) Inomata?et al. (2014) Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis; Respir. Res.,?15?16
6) Tanaka?et al. (2008)?Increased glutathione level is not involved in enhanced bleomycin sensitivity in cisplatin-resistant 2780CP cells; Anticancer Res.,?28?2663 |
|
|